News Pfizer's $2bn+ obesity bet, and other weight-loss news Pfizer licenses another GLP-1 agonist, from YaoPharma, plus clinical updates from Zealand, Structure, Ascletis, Wave, and Boehringer Ingelheim.
News GSK strikes again, adding COPD candidate in $745m deal In its second pipeline-expanding deal in 24 hours, GSK has licensed rights to a drug for COPD from US biotech Empirico for $85m upfront.
News As Blenrep returns, GSK adds another ADC to cancer pipeline GSK has boosted its pipeline of antibody-drug conjugates for cancer, licensing a prostate cancer candidate from Syndivia.
News Takeda builds in cancer with monster $11.4bn Innovent deal Takeda has partnered with China's Innovent for a pair of late-stage cancer therapies, in a deal that includes an upfront payment of $1.2bn.
News Novo builds pipeline again with $2.1bn Omeros deal Novo Nordisk has boosted its pipeline by paying $340m upfront for rights to an Omeros drug for PNH and other rare blood and kidney disorders.
News Angelini taps Sovargen for epilepsy drug in $550m deal Angelini Pharma has licensed a preclinical-stage mTOR inhibitor from South Korean biotech Sovargen with potential for genetic forms of epilepsy.
News Beren's Niemann-Pick drug Lembaz cleared by FDA The FDA has approved Beren's Lembaz for Niemann-Pick disease type C, the first drug shown to extend survival in the ultra-rare inherited disorder.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.